Individual-level Association of Influenza Infection With Subsequent Pneumonia: A Case-control and Prospective Cohort Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
06 12 2021
Historique:
received: 18 05 2020
accepted: 21 07 2020
pubmed: 28 7 2020
medline: 15 3 2022
entrez: 28 7 2020
Statut: ppublish

Résumé

Pneumonia is a leading cause of mortality worldwide. Influenza may result in primary pneumonia or be associated with secondary bacterial pneumonia. While the association with secondary pneumonia has been established ecologically, individual-level evidence remains sparse and the risk period for pneumonia following influenza poorly defined. We conducted a matched case-control study and a prospective cohort study among Nicaraguan children aged 0-14 years from 2011 through 2018. Physicians diagnosed pneumonia cases based on Integrated Management for Childhood Illness guidelines. Cases were matched with up to 4 controls on age (months) and study week. We fit conditional logistic regression models to assess the association between influenza subtype and subsequent pneumonia development, and a Bayesian nonlinear survival model to estimate pneumonia hazard following influenza. Participants with influenza had greater risk of developing pneumonia in the 30 days following onset compared to those without influenza (matched odds ratio [mOR], 2.7 [95% confidence interval {CI}, 1.9-3.9]). Odds of developing pneumonia were highest for participants following A(H1N1)pdm09 illness (mOR, 3.7 [95% CI, 2.0-6.9]), followed by influenza B and A(H3N2). Participants' odds of pneumonia following influenza were not constant, showing distinct peaks 0-6 days (mOR, 8.3 [95% CI, 4.8-14.5] days) and 14-20 (mOR, 2.5 [95% CI, 1.1-5.5] days) after influenza infection. Influenza is a significant driver of both primary and secondary pneumonia among children. The presence of distinct periods of elevated pneumonia risk in the 30 days following influenza supports multiple etiological pathways.

Sections du résumé

BACKGROUND
Pneumonia is a leading cause of mortality worldwide. Influenza may result in primary pneumonia or be associated with secondary bacterial pneumonia. While the association with secondary pneumonia has been established ecologically, individual-level evidence remains sparse and the risk period for pneumonia following influenza poorly defined.
METHODS
We conducted a matched case-control study and a prospective cohort study among Nicaraguan children aged 0-14 years from 2011 through 2018. Physicians diagnosed pneumonia cases based on Integrated Management for Childhood Illness guidelines. Cases were matched with up to 4 controls on age (months) and study week. We fit conditional logistic regression models to assess the association between influenza subtype and subsequent pneumonia development, and a Bayesian nonlinear survival model to estimate pneumonia hazard following influenza.
RESULTS
Participants with influenza had greater risk of developing pneumonia in the 30 days following onset compared to those without influenza (matched odds ratio [mOR], 2.7 [95% confidence interval {CI}, 1.9-3.9]). Odds of developing pneumonia were highest for participants following A(H1N1)pdm09 illness (mOR, 3.7 [95% CI, 2.0-6.9]), followed by influenza B and A(H3N2). Participants' odds of pneumonia following influenza were not constant, showing distinct peaks 0-6 days (mOR, 8.3 [95% CI, 4.8-14.5] days) and 14-20 (mOR, 2.5 [95% CI, 1.1-5.5] days) after influenza infection.
CONCLUSIONS
Influenza is a significant driver of both primary and secondary pneumonia among children. The presence of distinct periods of elevated pneumonia risk in the 30 days following influenza supports multiple etiological pathways.

Identifiants

pubmed: 32717069
pii: 5876899
doi: 10.1093/cid/ciaa1053
pmc: PMC8662761
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e4288-e4295

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001138
Pays : United States
Organisme : NIH HHS
ID : U01 A1088654
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
Lancet. 2013 Apr 20;381(9875):1405-1416
pubmed: 23582727
BMJ Open. 2018 Apr 21;8(4):e019743
pubmed: 29680810
Nat Immunol. 2018 Dec;19(12):1299-1308
pubmed: 30374129
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
Clin Microbiol Infect. 2014 Dec;20(12):O1088-90
pubmed: 24977322
Lancet. 2011 Apr 9;377(9773):1264-75
pubmed: 21435708
Clin Microbiol Rev. 2006 Jul;19(3):571-82
pubmed: 16847087
J Infect Dis. 2008 Oct 1;198(7):962-70
pubmed: 18710327
J Glob Health. 2015 Jun;5(1):010408
pubmed: 26445672
BMC Infect Dis. 2018 Dec 7;18(1):637
pubmed: 30526505
Clin Infect Dis. 2020 May 6;70(10):2029-2035
pubmed: 31257406
Vaccine. 2018 Jan 2;36(1):141-147
pubmed: 29157959
Clin Infect Dis. 2017 Aug 15;65(4):604-612
pubmed: 28605562
PLoS One. 2010 Nov 30;5(11):e15098
pubmed: 21152047
Lancet Respir Med. 2016 Jun;4(6):463-72
pubmed: 27117547
Clin Infect Dis. 2010 Jan 15;50(2):175-83
pubmed: 20014948
Vaccine. 2009 Aug 21;27 Suppl 3:C9-C14
pubmed: 19683658
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2765-72
pubmed: 22549730
Front Microbiol. 2017 Jun 23;8:1041
pubmed: 28690590
Am J Epidemiol. 2018 Dec 1;187(12):2511-2523
pubmed: 30124746
BMC Infect Dis. 2015 Nov 09;15:504
pubmed: 26553094
J Infect Dis. 2013 Apr;207(7):1135-43
pubmed: 23303809
Front Immunol. 2018 Nov 16;9:2640
pubmed: 30505304
Clin Infect Dis. 2000 May;30(5):784-9
pubmed: 10816149
Biometrics. 1978 Mar;34(1):57-67
pubmed: 630037
Med J Aust. 2011 Feb 21;194(4):207
pubmed: 21401468
Pediatr Infect Dis J. 2014 Jun;33(6):637-42
pubmed: 24445827
J Infect Dis. 2012 Feb 1;205(3):458-65
pubmed: 22158564

Auteurs

John Kubale (J)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Guillermina Kuan (G)

Sócrates Flores Vivas Health Center, Ministry of Health, Managua, Nicaragua.

Lionel Gresh (L)

Sustainable Sciences Institute, Managua, Nicaragua.

Sergio Ojeda (S)

Sustainable Sciences Institute, Managua, Nicaragua.

Amy Schiller (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Nery Sanchez (N)

Sustainable Sciences Institute, Managua, Nicaragua.

Roger Lopez (R)

Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Eduardo Azziz-Baumgartner (E)

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Steph Wraith (S)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Eva Harris (E)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, USA.

Angel Balmaseda (A)

Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Jon Zelner (J)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Aubree Gordon (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH